Industry speeds up the development of bispecific antibodies
By Son, Hyung Min | translator Alice Kang
24.12.02 05:45:10
가나다라
0
companies start developing bispecific antibody that targets bispecific antibody-drug conjugate (ADC) immuno-oncology drugs
GC Biopharma, Hanmi Pharmaceutical, ABL Bio makes bid into the industry
The Korean pharmaceutical industry is accelerating the clinical trials of bispecific antibodies to secure solid tumor indications. Bispecific antibodies, which have an additional specific antigen binding site compared to monoclonal antibodies, are recognized for their clinical benefits. GC Biopharma, Hanmi Pharmaceutical, ABL Bio, and Immuneoncia are among the companies developing bispecific antibodies for solid tumors.
According to industry sources on the 30th, GC Biopharma recently signed a memorandum of understanding with Kanaph Therapeutics to develop a bispecific antibody-drug conjugate (ADC).
▲GC Biopharma and Kanaph Therapeutics starts development of a bispecific antibody
▲GC Biopharma and Kanaph Therapeutics starts development of a bispecific antibody
The agreement, which includes an exclusive right for options, allows GC
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)